
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=undefined&type=result"></script>');
-->
</script>
A peer-reviewed antibody characterization article corresponding to this Zenodo preprint is openly available at F1000Research: https://doi.org/10.12688/f1000research.132249.1 Head-to-head comparison of available commercial antibodies against Profilin-1 by immunoblot (Western blot), immunoprecipitation and immunofluorescence. Work reported in this report was supported in part by the ALS-Reproducible Antibody Platform (ALS-RAP). ALS-RAP was created as a public-private partnership by three leading ALS charities: the ALS Association (USA), the Motor Neurone Disease Association (UK), and the ALS Society of Canada.
amyotrophic lateral sclerosis, antibody characterization, P07737, PFN1, Profilin-1, antibody validation, ALS-RAP
amyotrophic lateral sclerosis, antibody characterization, P07737, PFN1, Profilin-1, antibody validation, ALS-RAP
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 1 | |
popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
views | 77 | |
downloads | 25 |